Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“A few highlights from my ADC resistance talk at LACOG-GBECAM 2025.
- T-DXd works after T-DM1, diff payload, stronger ADC
- 2nd TOP1 ADC performs inferiorly, unclear who benefits >1
- Mutations in TROP2 and TOP1–> resistance
- Downregulation of target occurs after T-DXd treatment
- We need new ADCs with diverse payloads
I love Brazil!”
